Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
Globe Newswire•13/08/2026•16:00 ET
0
Whiz Insights
– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) –
– Completed $115 million gross financing to support advancement of pipeline programs through key development milestones –
Get started
Create a free account to read the full story.